It is recommended to perform NGS-based BRCA1/2 somatic and germline testing when evaluating advanced prostate cancer patients to identify potential familial cancers and to utilize PARP inhibitors or platinum-based chemotherapies when the disease progresses to mCRPC [2,37]. The gene discussed is BRCA1; the disease is prostate carcinoma.